Bachem renews supply contract with AstraZeneca
The Bachem Group announced the renewal of its supply agreement with AstraZeneca for the peptide active substance goserelin. The extended partnership enhances the cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years. Bachem has been supplying AstraZeneca with Goserelin for more than 25 years.
Dr. José de Chastonay, Chief Marketing Officer of the Bachem Group, commented: “This renewed long-term sales agreement emphasizes the high competitiveness of our products and services. For Bachem, it is also a clear validation of its market position as Pioneering Partner for Peptides. We are delighted about the renewed supply agreement as part of our very successful and long-standing partnership with AstraZeneca.”
Other news from the department business & finance
